{
    "clinical_study": {
        "@rank": "88968", 
        "acronym": "ADAPT", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "Trastuzumab + Pertuzumab"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Active Comparator", 
                "description": "Trastuzumab + Pertuzumab + Paclitaxel"
            }
        ], 
        "brief_summary": {
            "textblock": "Trial to evaluate efficacy of dual blockade with two anti-HER2 agents with or without\n      chemotherapy backbone within the ADAPT trial."
        }, 
        "brief_title": "A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol", 
        "completion_date": {
            "#text": "August 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female patients, age at diagnosis 18 - 75 years\n\n          -  Histologically confirmed unilateral primary invasive carcinoma of the breast\n\n          -  Clinical T1 - T4 (except inflammatory breast cancer)\n\n          -  All clinical N (cN)\n\n          -  No clinical evidence for distant metastasis (M0)\n\n          -  Known HR status and HER2 status (local pathology) Tumor block available for central\n             pathology review\n\n          -  Performance Status ECOG \u2264 1 or KI \u2265 80%\n\n          -  Negative pregnancy test (urine or serum) within 7 days prior to start of induction\n             treatment in premenopausal patients\n\n          -  Written informed consent prior to beginning specific protocol procedures, including\n             expected cooperation of the patients for the treatment and follow-up, must be\n             obtained and documented according to the local regulatory requirements\n\n          -  The patient must be accessible for treatment and follow-up\n\n        Additional Inclusion criteria for participation in the HR-/HER2+ sub-protocol:\n\n          -  Confirmed ER and PR negative and HER2+ by central pathology\n\n          -  Clinical cT1c - T4a-c (participation of patients with tumors >cT2 is strongly\n             recommended)\n\n          -  All clinical N (participation of patients with cN0, if at least cT1c is strongly\n             recommended)\n\n          -  Patients must qualify for neoadjuvant treatment\n\n          -  LVEF > 50%; LVEF within normal limits of each institution measured by\n             echocardiography and normal ECG (within 42 days prior to induction treatment)\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity reaction to the compounds or incorporated substances\n\n          -  Prior malignancy with a disease-free survival of < 10 years, except curatively\n             treated basalioma of the skin, pTis of the cervix uteri\n\n          -  Non-operable breast cancer including inflammatory breast cancer\n\n          -  Previous or concurrent treatment with cytotoxic agents for any reason after\n             consultation with the sponsor\n\n          -  Concurrent treatment with other experimental drugs. Participation in another clinical\n             trial with any investigational not marketed drug within 30 days prior to study entry\n\n          -  Male breast cancer\n\n          -  Concurrent pregnancy; patients of childbearing potential must implement a highly\n             effective (less than 1% failure rate) non-hormonal contraceptive measures during the\n             study treatment\n\n          -  Breast feeding woman\n\n          -  Sequential breast cancer\n\n          -  Reasons indicating risk of poor compliance Patient not able to consent\n\n        Additional Exclusion Criteria for participation in the HER2+/HR- sub-protocol:\n\n          -  Known polyneuropathy \u2265 grade 2\n\n          -  Severe and relevant co-morbidity that would interact with the application of\n             cytotoxic agents or the participation in the study\n\n          -  Inadequate organ function (e.g. hepatic impairment, pulmonary disease, etc.)\n\n          -  Uncompensated cardiac function (current unstable ventricular arrhythmia requiring\n             treatment, history of symptomatic CHF NYHA classes II-IV), history of myocardial\n             infarction or unstable angina pectoris within 6 months of enrollment, history of\n             severe hypertension, CAD - coronary artery disease)\n\n          -  Severe dyspnea\n\n          -  Abnormal blood values:\n\n          -  Thrombocytopenia > CTCAE grade 1\n\n          -  Increases in ALT/AST > CTCAE grade 1\n\n          -  Hypokalaemia > CTCAE grade 1\n\n          -  Neutropenia > CTCAE grade 1\n\n          -  Anaemia > CTCAE grade 1"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01817452", 
            "org_study_id": "WSG-AM06 / ADAPT HER2+/HR-"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B"
                ], 
                "intervention_name": "Trastuzumab", 
                "intervention_type": "Drug", 
                "other_name": "Herceptin"
            }, 
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B"
                ], 
                "intervention_name": "Pertuzumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Paclitaxel", 
                "Trastuzumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "contact": {
                "email": "ulrike.nitz@wsg-online.com", 
                "last_name": "Ulrike Nitz, Prof. Dr.", 
                "phone": "+492161981", 
                "phone_ext": "2330"
            }, 
            "facility": {
                "address": {
                    "city": "Moenchengladbach", 
                    "country": "Germany", 
                    "zip": "41061"
                }, 
                "name": "Ev. Krankenhaus Bethesda Brustzentrum Niederrhien"
            }, 
            "investigator": {
                "last_name": "Raquel von Schumann, Dr.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol", 
        "overall_contact": {
            "email": "daniel.hofmann@wsg-online.com", 
            "last_name": "Daniel Hofmann, M. Sc.", 
            "phone": "+49216156623", 
            "phone_ext": "17"
        }, 
        "overall_official": [
            {
                "affiliation": "Breast Center of the University of Munich (LMU), Universit\u00e4tsfrauenklinik Gro\u00dfhadern, Munich, Germany", 
                "last_name": "Nadia Harbeck, Prof. Dr.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, M\u00f6nchengladbach, Germany", 
                "last_name": "Ulrike Nitz, Prof. Dr.", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "pCR will be measured after 12 weeks of randomized treatment.", 
            "measure": "Definition of a biomarker (profile) characterizing \"good responders\" to dual blockade T and P anti-HER2 blockade that have similar pCR rates as patients treated with identical dual anti-HER2 blockade + taxane backbone", 
            "safety_issue": "Yes", 
            "time_frame": "After 12 weeks of therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01817452"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "West German Study Group", 
        "sponsors": {
            "collaborator": {
                "agency": "Roche Pharma AG", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "West German Study Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}